

CSCB Virtual Seminar Series

Targetable oncogenic signalling in ALT cancers.

Date: 16th August 2021 (Monday)

Time: 12noon-1pm (SGT)

Venue: via Zoom

<https://nus-sg.zoom.us/j/81481605559>

Meeting ID: 814 8160 5559

Passcode: 563809

Abstract:

Enabling replicative immortality is one prominent feature of cancer cells. To that end, cancer cells activate means to elongate their telomeres. While 85% of cancers re-express telomerase, around 15% of all cancers rely on the ALT (Alternative Lengthening of Telomeres) mechanism. Despite its frequency, no clinically approved ALT-targeted therapy exists to date. In this talk, I will present our strategies to find anti-cancer compounds that affect the proliferation and telomeric homeostasis of ALT cancer cells and highlight the example of an RTKI (Receptor Tyrosine Kinase Inhibitor), which we identified to be dysregulating ALT activity. Furthermore, I will delineate the approaches we took to decipher the RTKI-inhibited signalling networks which are impacting the telomeres of ALT cells. Overall, our research aims to provide a deeper understanding and preclinical testing of actionable targets in ALT tumors

Speaker:



Dr. Maya Jeitany

Presidential Postdoctoral Fellow
Nanyang Technological University

Dr. Maya Jeitany graduated in 2014 from Paris Descartes University with a PhD degree in Molecular and Cell Biology, carried out at the CEA (Commissariat à l'Énergie Atomique) Institute thanks to the competitive "Irtelis PhD program" funding scheme. After graduation, she joined the Montpellier Cell Biology Research Center and subsequently the Cancer Science Institute of Singapore for postdoctoral stints. In 2019, she joined NTU as a Presidential Postdoctoral Fellow.

Host:

David Virshup

Professor & Director
Programme in Cancer & Stem Cell Biology
Duke-NUS Medical School
Singapore

**No registration is required.
All are welcome.**